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3. Preface 
 
Peptide drugs: prospects and challenges 
 
Molecular recognition of the effector molecule is the determining step in any biological signal 
transduction. Many effector molecules that trigger cellular biochemical events are peptides with the 
recognition site representing either a part of a larger protein or a stand-alone, functionally complete 
moiety. With the average size of eleven amino acids (from few to about 40 residues), a recognition 
sequence required for a receptor-ligand interaction is rather short,[1] implying that in principle all 
receptors could be regulated by artificial peptides.[2] Today, more than 7000 naturally occurring 
peptidic molecules have been identified that act as hormones, neurotransmitters and growth factors or 
are involved into defence against pathogens.[1a, 3]  
 
The variety of side-chain functional groups endows peptides with the ability to form numerous 
interactions with their targets. As a consequence, the high selectivity of peptidic drugs provides an 
option to reduce side effects, thus enabling good tolerance. Due to their structural diversity, peptides 
are suitable for the (almost unlimited) application in the fields of oncology, endocrinology, 
immunology, and for the control of infectious diseases. Currently, more than 100 peptidic drugs have 
been approved, the majority of them possessing less than 20 amino acids.[4] Approximately 200 
peptides have been to date investigated in clinical trials and another 400 are in early preclinical 
development.[4-5] Simple synthetic manufacturing combined with good predictability of metabolism[5b] 
makes peptidic drugs particularly attractive.  
 
However, peptide drugs often suffer from limited bioavailability and metabolic instability mainly 
caused by hydrolysis and oxidation reactions.[6] Additionally, their bioavailability can be compromised 
upon opsonisation, agglutination, and non-covalent association with serum components.[7] To date, a 
number of approaches has been developed aimed on the improvement of systemic availability and 
site-selective delivery of peptide drug candidates. Thus, the stability of such architectures can be 
increased upon substitution of certain amino acids or modification/removal of potential protease 
binding sites. Aggregation can be reduced by avoiding hydrophobic regions or by modulating 
isoelectric point using amino acid exchange.[6] Stability towards proteolytic degradation can be 
enhanced by cyclization and/or incorporation of non-canonic amino acids or backbone elements.[3a, 8] 
Furthermore, the pharmacokinetics of peptides has been significantly improved upon PEGylation and 
fusion with vitamin B12, as well as by conjugation with fatty acids.[9]  
 
Oligomerization represents another important strategy towards the improvement of peptidic drugs. 
Indeed, linkage of monomeric counterparts leading to higher-ordered constructs provides a number of 
advantages in terms of stability. One possibility to improve the half-life of peptidic molecules in the 
bloodstream is to increase their size. Upon intravenous application, compounds with a molecular mass 
lower than 5500 Dalton are quickly renal secreted as their size enables the passage through the pores 
of the nephron in the kidney. Larger molecules possess longer half-lives in the bloodstream.[10] 
Conjugation of multiple peptides could therefore lead to increased plasma circulation time. 
Furthermore, being involved in numerous biological processes, oligomeric protein structures are 
ubiquitous structural motives in nature. Molecular architectures comprising n>1 copies of identical 
biomolecules could enable modulation of certain regulatory processes inside the cell as e.g. the growth 
factor thrombopoietin does. This dimeric cytokine controls proliferation, cell maturation, as well as the 
production of thrombocytes by inducing the formation of a homodimer of the respective receptor on 
the cell surface.[11] Obviously, such intracellular events could be regulated applying structurally similar 
oligomers of synthetic peptides (scheme 1a).  
 
Oligomerization of functional peptidic monomers can improve their binding to the desired 
extracellular targets. It is obvious that if the local concentration of the ligand in spatial proximity to a 
binding site increases, the probability of additional interactions is increased as well. Thereby, spatial 
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separation of the oligomeric binder and the binding site can be prevented. Due to this effect called 
avidity, strong binding strength can be achieved also for low-affinity peptide monomers (scheme 
1b).[12] This approach can find application in e.g. diagnostics of tumour disease via medical imaging 
technique, as oligomerization can simultaneously improve both pharmacokinetics and binding 
strength. As the stability of the oligomeric construct can be tailored, the retention time inside the body 
can be precisely adjusted, thus allowing for e.g. reduced exposure to radionuclides.  
 
 
Scheme 1: Modulation of intracellular processes by using n>1 copies of identical biomolecules. a) Induction of 
homodimer-formation of cell-surface receptors. b) Increasing binding strength upon formation of multiple interactions. 
 
In addition to the mentioned extracellular applications, peptides are suited for the control of signal 
transduction inside the cell, too. However, due to the relatively high molecular mass and particularly 
charged functional groups, intracellular bioavailability of these molecules is fundamentally restricted. 
They are not able to cross epithelial barriers and cellular membranes.[13] The membrane translocation 
of peptides can be improved by decreasing their polarity via the introduction of hydrophobic amino 
acids or lipophilic building blocks. Cellular uptake of functional peptidic molecules can be enabled 
upon their co-administration/fusion with the so-called cell-penetrating peptides (CPPs) or via the 
attachment of ligands possessing affinity to surface receptors (e. g. carbohydrate or lipoprotein 
receptors).[4, 14]  
 
Though being promising drug candidates, the majority of peptides are poor orally available. Indeed, 
due to the degradation in the gastrointestinal tract and limited tissue absorption, the current 
administration is predominantly intravenous or subcutaneous.[15] Realization of oral availability of 
peptidic drugs via e.g. their chemical stabilization or co-administration with absorption enhancers and 
enzyme inhibitors would be a significant improvement from the standpoint of the patient. 
 
Drug delivery as a cornerstone for future-oriented therapeutic approaches 
 
Despite significant achievements in recent years, the transport of peptides remains the major handicap 
limiting their therapeutic application. This extends to all modern therapeutic approaches based on the 
application of biomacromolecules, especially those composed of amino and nucleic acids. Indeed, by 
import of nucleic acids, living cells can be manipulated in different ways. To date, a variety of highly 
innovative technologies based on tailor-made DNA and RNA constructs has been developed, which 
carry an impressive potential for ground-breaking improvements in medical treatments. However, 
these novel approaches often require efficient intracellular transporters. Thus, genome editing requires 
delivery of respective programmable nucleases into the cells of interest.[16] Also for siRNA which 
enables gene silencing by tagging the corresponding mRNA, thereby initiating its degradation, efficient 
import is currently the biggest challenge.[17] Development of viable approaches aimed on the induction 
of biosynthesis of therapeutic proteins in the organism of the patient is another future-oriented 
research field. To launch protein synthesis, the required genetic information must be either transiently 
(mRNA) or permanently (DNA) available inside the cell. Therefore, as soon as the desired nucleotide-
comprising constructs have reached the cell interior, the production of e.g. monoclonal antibodies in 
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the patient’s body is ensured. This methodology could obviate the need for side-effect-afflicted high-
dose injections and would significantly contribute to a reduction of the treatment costs.[18]  
 
In order to translate the above-mentioned innovative approaches into clinical practice, efficient 
transport and site-specific release in the desired cellular compartments is essential. As a consequence, 
the development of a viable carrier system becomes as important as the ability of the drug to address 
its target. A proper delivery platform should enable efficient and safe cellular import of the desired 
cargo. Thus, to protect biomacromolecules from degradation upon transport, they can be deposited 
into polymers, nano-emulsions, hydrogels, or particles of nano-dimension.[19] To date, a variety of 
nanoparticle formulations has been applied to the delivery of proteins (antibodies, enzymes, etc.) and 
nucleotide-based constructs (plasmid-DNA, siRNA, mRNA, etc.). In contrast to the majority of proteins 
or peptides often addressing surface-bound targets, nucleic acids need to be delivered into the 
cytoplasm or the nucleus. Current transport systems for these compounds are composed of positively 
charged polymers, cationic lipids, as well as viral vectors.[17] Following cellular uptake, nanoparticles 
are commonly processed to the early and late endosomes and, as a rule, the cargo is degraded in the 
Golgi network. Strategies to bypass this degradation pathway are based on hampering the acidification 
in the late endosomes via the so-called proton sponge effect caused by basic functional groups, usually 
amines or imines within the used polymeric delivery module. As an alternative, application of lipid 
nanoparticles can enable release of the cargo upon its fusion with the endosomal membrane or 
pH-dependet changes of the conformation of certain peptides can lead to pore formation 




Scheme 2: Current drug delivery strategies allowing either for systemic or intracellular delivery of complex biomolecules 
enabeling future-oriented technologies as e. g. gene silencing, genome editing, and biosynthesis of proteins.[21] 
 
In addition to nanoparticle-based transport systems, cell-penetrating peptides (CPPs) are in research 
focus since almost two decades.[22] Following different mechanisms, cationic peptides enable highly 
efficient membrane transduction. It has been shown that conjugation of numerous cargoes, e.g. small 
molecules, antibodies, peptides, proteins, nucleic acids, as well as transport systems like liposomes or 
nanoparticles, with CPPs is able to improve their membrane translocation.[23] The applicability of cell-
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penetrating peptides for drug delivery is currently in early clinical trials.[23]  However, despite these 
impressive achievements, CPPs still possess significant drawbacks and need to be optimized with 
respect to stability, toxicity and uptake efficacy. Additionally, large-scale synthesis of cell-penetrating 
peptides is time-consuming and expensive; moreover, the peptidic structure limits the possibilities for 
optimization. These intrinsic handicaps can be omitted by using inert scaffold molecules lacking 
needless, in terms of function, structural moieties e. g. peptide backbone. Being potentially labile, 
these elements can in fact compromise the overall stability of the carrier. In general, exclusively the 
number and the spatial arrangement of the functional groups endowing the carrier with the ability to 
penetrate cells is crucial for the efficacy of such molecular transporters.[24] In order to maximize 
cellular uptake, compact and rigid assembly of functional groups is beneficial.  
 
Molecular scaffolds that almost perfectly meet these requirements are polyhedral silsesquioxanes. They 
compose a particular class of silicon oxide nanoparticles comprising an inert inorganic core of mutually 
alternating Si and O atoms. Similar to silicone polymers, Si atoms can bear organic groups carrying a 
variety of addressable functional moieties. Due to their biocompatibility, silicones are used in many 
medical fields, and silsesquioxanes have found their application in medical engineering (for e.g. 
structuring of silicon resins), too.[25] Some silsesquioxane derivatives are hydrolysed under 
physiological conditions resulting in a mixture of primary and secondary siloxanes.[26] The duration of 
such processes strongly depends on the functional groups attached to the inorganic core and can 
therefore be tuned by appropriate selection of the organic residues.[27] The smallest representatives of 
this class of organic-inorganic hybrid molecules are cube-octameric silsesquioxanes (COSS). Its 
inorganic core is arranged in a cage-like structure and comprises a size of less than 1 nm.[28] Up to 
eight organic residues can be attached to the silicon atoms (scheme 3). Such high valency in 
combination with the small size and the highly defined structure makes COSS an attractive scaffold for 
medical applications. Today, COSS are manufactured on a large scale and a variety of inexpensive 
derivatives is commercially available.[29]  
 
 
Scheme 3: a) Molecular structure of octakis(3-aminopropyl)octasilsesquioxane. b) Space-filling model of the inorganic core of 
COSS composed of Si (yellow) and O (red). For clarity, hydrogen (white) substituted COSS is shown. c) Space-filling model of 
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Objectives 
 
1. The present cumulative dissertation is focused on the investigation of silsesquioxane 
nanoparticles as modular multifunctional platforms for the application in biomedical 
engineering and associated research areas. To itemize, COSS modules were considered as 
molecular frameworks for the intracellular delivery of bioactive cargoes. Indeed, the unique 
architecture of cube-octameric silsesquioxanes allows to tailor their pendant groups in such a 
way that efficient cell penetration could be achieved. On the other hand, each cargo of interest 
could be covalently attached to the COSS scaffold at the desired (up to eight monomers) 
oligomerization degree. To achieve these goals, several issues have to be addressed. 
 
2. A simple and efficient method for the biofunctionalization of COSS scaffolds must be 
elaborated, providing compatibility with multifunctional biomolecules and support integrity of 
the siloxane core. To this end, the focus was set on site-selective covalent attachment of 
bioactive peptides of different size and molecular complexity.  
 
3. Taking into consideration the limited stability of COSS system in the presence of certain 
nucleophiles, a viable functionalization strategy must be developed that is based on efficient 
biorthogonal transformations. This synthetic scheme must allow for the controlled, single-
corner COSS derivatization with the molecules of peptidic nature. 
 
4. The suitability of COSS as a drug delivery vehicle should be evaluated upon import of an 
engineered peptidic cargo targeting a particular cellular compartment in living mammalian 
cells. The effects of the carrier on biological systems must be studied in vitro. 
 
5. Engineering of COSS scaffold to improve its cell-penetrating efficiency must be conducted. 
Thus, based on the knowledge on permeation mechanisms and chemical moieties required, the 
pendant groups must be suitably manipulated. The required chemistry must be established, and 
the properties of novel compounds have to be studied in detail. In order to assess the potency 
of novel COSS derivatives in cell experiments, the proper reporter and chemistry for its 
covalent attachment must be considered as well.  
 
6. The biological effects of the novel cell-penetrating COSS modules must be carefully 
investigated with respect to their potential medical applications. This includes studies on 





For functionalization with peptides and miniproteins, COSS bearing eight aminopropyl groups was 
selected as starting material (discussed in section 8.1). Although pendant amine groups allowed to 
apply a vast arsenal of nucleophile-comprising chemical modifications, the synthetic procedure had to 
be carefully designed. Indeed, an intramolecular attack of the amino groups on the inorganic core 
leads to degradation of the siloxane cage following the so-called “back-bite” mechanism.[27] To avoid 
this uncontrolled degradation, all synthesis requiring basic reaction conditions were performed in dry 
solvents. Due to high polarity of octakis COSS derivative, only N,N’-dimethylsulfoxide (DMSO) was 
suited as a solvent for the introduction of functional groups at ambient temperature. In order to avoid 
thermal stress, the solvent was removed by lyophilisation.  
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In the present work, the amino groups were either transformed into different functional groups in 
order to modify the biological features of COSS, or were used for the introduction of functional groups 
allowing for the coupling of complex biomolecules. Functional groups allowing for the attachment of 
peptides and miniproteins were designed according to the repertoire of conjugation methods that can 
be applied to both peptidic and COSS counterparts. In general, besides high coupling efficacy the 
method must be biorthogonal and has to ensure the integrity of the inorganic core. Depending on the 
desired application, different coupling strategies have been selected and diverse ligation methods were 
established (Table 1). Thus, the well-established base-promoted conjugation via activated carboxylic 
acid was found inadequate due to the lack of selectivity. On the other hand, formation of a thioether 
between maleimide-bearing COSS and thiol-decorated peptides (i.e. those containing an additional 
cysteine residue) proceeded smoothly and was found suitable for the peptides lacking disulfide bonds. 
However, this method could not be applied to the cystine-rich molecules as e.g. knotted miniproteins. 
For the same reason, the promising thiazolidine ligation between an aldehyde and an aminoterminal 
cysteine had to be withdrawn.[31] The copper-catalyzed azide-alkyne cycloaddition that shows its 
maximal efficiency under alkaline aqueous conditions did not demonstrate its benefits in dry 
solvents.[32] Due to steric hindrance caused by the bulky and hydrophobic alkyne-bearing moieties, the 
copper-free version of this reaction was discarded as well.  
 
Finally, the oxime ligation between aminooxy and aldehydic groups was identified as a viable coupling 
strategy.[33] Indeed, reactive carbonyls can be easily installed into biomolecules enzymatically[34] or 
upon periodate- or pyridoxal phosphate-mediated oxidation of certain N-terminal amino acids.[35] As 
the oxime ligation is carried out under acidic conditions, the integrity of the inorganic core of COSS is 
ensured in aqueous reaction media as well. Because aldehydes can be easily introduced into 
(oligo)saccharides by oxidation of their hydroxyls by sodium periodate, this ligation strategy can be 
considered as a versatile and highly efficient way towards biofunctionalization of COSS. Being applied 
to COSS functionalization with peptides of different length and architecture, this reaction enabled 
coupling of up to eight (in the case of peptides comprising 9-35 amino acids) and up to three (in the 
case of miniproteins with about 30 amino acids and three disulfide bonds) copies within few hours at 
ambient temperature. Oligomerization on the COSS scaffold did not compromise bioactivity of 
matriptase-1 inhibitors, as confirmed in an enzymatic assay.[36] 
 
  Table 1: Coupling strategies for biofunctionalization of COSS. 
 
Coupling strategy Functional groups involved Applicability 
Amide coupling 
Activated carboxylic acid and 
amine 
Not applicable due to lack of selectivity 
Thioether formation Maleimide and sulfhydryl 
Suitable for peptides lacking disufide 
bonds; not applicable to cystine-rich 
molecules 
Thiazolidine formation 
N-termially installed cysteine and 
aldehyde 
Suitable for peptides lacking disufide 
bonds. Not applicable to cystine-rich 
molecules 
Copper-catalyzed azide-
alkyne cycloaddition  
Azide and alkyne 
Not applicable to complex peptides due to 
compromized efficacy in dry solvents 
Strain-promoted azide-
alkyne cycloaddition  
Azide and alkyne-bearing moiety 
Not applicable due to bulky and 
hydrophobic alkyne-bearing moieties 
Oxime ligation Aminooxy and aldehyde 
Applicable for conjugation of peptides of 
different length and architecture 
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Synthesized compounds were fully characterized by the appropriate analytical methods. The stability 
of COSS-oligomerised peptides was investigated under physiological conditions by size-exclusion 
chromatography. Whereas the inorganic core of fully-loaded peptide-COSS conjugates was found to be 
stable for at least 12 hours, degradation of partially functionalized cages occurred within few hours 
resulting in breakdown of the COSS oligomers. These observations indicate that the stability of the 
system can be customized to the individual needs by proper selection of the COSS pendant groups, 
conjugated ligands, and degree of oligomerization. In the case of binding peptides, COSS-based 
oligomers could contribute to tumour diagnostics by medical imaging as application of these constructs 
could improve both pharmacodynamics and binding strength. As the hydrolysis rate can be tuned, the 
patient exposure time to e. g. radioactive nuclides can be reduced.  
 
Besides the establishment of an efficient method for oligomerization of peptides, the catalyst-free 
inverse electron demand Diels-Alder reaction (DARINV) (section 8.2) and disulfide-bond formation 
were successfully applied to single-corner modification of COSS scaffold. The applicability of both 
methods, which allow for the introduction of at least two different sorts of addressable moieties, was 
experimentally confirmed. Due to the reductive milieu of the cytoplasm, conjugation via disulfide bond 
enables fast release of the cargo after cellular uptake and is therefore particularly of interest for drug 
delivery. 
 
In the frame of the present cumulative dissertation different COSS-based synthetic molecular 
transporters were developed with respect to cellular uptake and suitability for cargo transport. In the 
year 2005, COSS bearing seven aminopropyl groups has been found to be the smallest cell-penetrating 
nanoparticle to date.[37] To investigate whether polyhedral silsesquioxanes could serve as drug delivery 
modules, this heptaammonium COSS derivative was studied in detail (section 8.3). This study was 
aimed on functional transport of a peptide with low intrinsic membrane permeation ability in a cell 
culture experiment. By live-cell confocal imaging, efficient translocation of fluorescently labelled COSS 
in the nucleus was observed. In order to investigate suitability as a carrier molecule, a 17-residue 
peptide possessing high affinity towards the Proliferating Cell Nuclear Antigen (PCNA) was attached 
via a disulfide bond. PCNA is a DNA camp involved in DNA replication and repair. By live-cell confocal 
imaging, activity of the peptide after cellular uptake was proven by co-localization of the fluorescein-
labelled PCNA-binding peptide with its target PCNA, genetically fused to the red fluorescent protein. 
Hereby, for the first time selective labelling of an enzyme inside living cells was achieved by using a 
rather short oligopeptide. Furthermore, the COSS transport system was investigated by flow cytometry 
to quantify cellular uptake in mammalian cells. Its efficacy was found to be in the same order of 
magnitude as that for the cell-penetrating peptide Tat.[38] In case of this well-known transporter, six 
arginine and two lysine residues define its cell-penetrating behaviour. In contrast to Tat, the 
investigated COSS derivative bears seven aminopropyl groups only. Therefore, its surprisingly high 
cellular uptake can be attributed to the rigid and dense assembly of the functional groups surrounding 
the inorganic core. Indeed, a significant increase in cellular import was achieved by reduction of 
conformal freedom upon cyclization of cell-penetrating peptides.[24a] Furthermore, the cubic structure 
of COSS presumably associated with the formation of ordered structures, as well as the exceptional 
arrangement of the functional groups could contribute to the observed increase in activity.[39] Indeed, 
evidence for spontaneous formation of ordered structures was also found upon atomic force 
microscopy (AFM) investigations.[40] 
 
Since principle applicability of COSS for drug delivery was proven, the investigated COSS derivative 
was used as the starting point for the synthesis of improved transport systems. By chemical 
modification of the functional groups surrounding the COSS scaffold, the efficacy of cellular uptake 
was significantly improved. To this end, amine, guanidine, and trimethylammonium groups were 
installed at different remoteness from the inorganic core (section 8.4). Employing live-cell confocal 
imaging, intracellular localization of the fluorescently labelled COSS derivatives was verified in human 
cancer cell line HeLa. Thereby, more efficient cellular uptake and pronounced accumulation inside the 
nucleus was found for the compounds comprising shorter linkage between the siloxane core and the 
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charged counterparts. Less compact structure of COSS transporters (longer linkers) was associated 
with lower efficacy and cytoplasmic accumulation.  
By using flow cytometry, these delivery modules were compared to well-established cell-penetrating 
peptides as Tat, Penetratin, and polyarginines.[22] Compared to the starting heptaammonium COSS, 
installation of permanently positively charged tetrasubstituted ammonium groups improved cellular 
uptake. However, the most efficient transport in all investigated cell lines (HeLa, HEK-293, and CHO) 
was demonstrated by the derivative bearing seven densely arranged guanidinium groups (GuCOSS). In 
HeLa cells, this carrier was found to be more efficient than both Tat (approximately 157 times) and 
decaarginine. Interestingly, cellular uptake of GuCOSS was 35-fold higher compared to that of cell-
penetrating peptide heptaarginine, notwithstanding that both carriers bear the same number of 
identical guanidine groups. Thus, this gain in the efficacy can be attributed the unique, compact 
structure of the COSS scaffold. Additionally, fluorescence microscopy revealed indications for cellular 
uptake of the GuCOSS system in bacteria, yeasts and archaea. With regard to possible applications of 
GuCOSS as a molecular transporter for antibiotics, cellular uptake was in detail investigated in E. coli. 
To this end, bacteria were incubated with fluorescently labelled GuCOSS and solitary fluorescent dye 
tetramethylrhodamine (TAMRA), respectively. Whereas solitary TAMRA did not provide staining of 
bacteria, a strong fluorescence signal revealing for more than 36 hours was found when using labelled 
GuCOSS. As under physiological conditions the inorganic core of COSS degrades within this period 
and no staining of cells was observed with TAMRA alone, it could be concluded that the dye has been 
entrapped inside the cells.  
 
In order to characterize the transporter with respect to potential in vitro and in vivo applications, 
toxicity studies were performed in HeLa cells. Thus, the toxicity of GuCOSS was found to be 
comparable to that of the derivative investigated in section 8.3, as well as to common cell-penetrating 
peptides.[38] Since the hydrolytic degradation of the inorganic core of COSS was described in detail, the 
GuCOSS transport system was characterized with respect to its stability.[26] To that end, degradation 
was quantitatively investigated at different pH values in time-resolved HPLC analysis. Thereby, direct 
correlation between pH value and half-life of the carrier was found. Whereas the transporter was 
stable under acidic conditions, elevated concentrations of nucleophilic hydroxyl ions present already at 
neutral pH promoted decomposition of the inorganic core. The degradation mechanism of COSS was 
investigated using mass spectrometry. It was found that the cubic architecture of the core is initially 
disrupted upon nucleophilic attack of hydroxyl ions at the silicon atoms. Further incorporation of 
hydroxyl ions ultimately leads to separation of silicon atoms bearing functional groups, thus the ability 
to translocate cellular membranes is lost. Complete hydrolysis of the inorganic core results in the 
formation of monomeric and dimeric hydroxyorganosilanes.[26] By using an assay based on a Förster 
resonance energy transfer (FRET), degradation of the GuCOSS system was found after about 11 hours 
in human blood serum and inside living HeLa cells. As low-molecular-mass fragments can be easily 
secreted, no intracellular accumulation of GuCOSS is expected.  
 
Suitability of GuCOSS as a drug delivery vehicle was proven by transport of a model drug. For this 
experiment cytotoxic anti-cancer drug Doxorubicin was selected. By DNA intercalation, it interferes 
with DNA and RNA synthesis and inhibits Topoisomerase II, which results in the induction of cell 
death.[41] In cell culture experiments, COSS-conjugated Doxorubicin was significantly more effective 
than the solitary drug. As GuCOSS possesses good water solubility, it could serve as molecular 
transporter and solubility enhancer at the same time. Depending on the coupling strategy, either 
sustained release or immediate cleavage of the cargo inside the cell can be achieved. By control of the 
release rate, the intracellular localization of the cargo can be tailored as well. Due to rapid 
accumulation of the carrier in the nucleus, irreversible attachment using the DARINV described in 
section 8.2 can lead to sustained release upon hydrolytic degradation of the inorganic core. Thereby, a 
constant supply of this cellular compartment with the cargo of interest can be achieved. In recent 
years, bioorthogonality of the DARINV reaction has been demonstrated in numerous in vitro and in vivo 
studies. In the frame of the present research, it was proven that this coupling method is suited for 
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peptide conjugation due to its good to quantitative turnover rates.[42] This ligation approach was 
applied to the conjugation of peptides with silsesquioxane nanoparticles, too.  
In order to achieve rapid release inside the cytoplasm, additionally a covalent ligation strategy based 
on a redox-controlled disulfide bond was established. Disulfide bond was formed either under 
oxidation with hydrogen peroxide, or applying activation of one thiols by Aldrithiol. As the second 
procedure allows for selective coupling under mild reaction conditions, this synthesis route should be 
concerned as the method of choice.  
 
To summarize, different generally applicable and highly efficient conjugation methods were 
established for biofunctionalization of COSS with peptides and small molecules. Thereby, this unique 
scaffold molecule was made accessible for a vast number of scientific approaches based on 
oligomerization of biomolecules. Furthermore, a novel molecular transporter allowing for efficient 
cellular delivery of drugs and superior to common cell-penetrating peptides was developed. With its 
simple synthesis and the defined half-life under physiological conditions, GuCOSS could serve as a 
platform enabling future-oriented scientific and clinical approaches. 
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4. Summary 
 
Cube-octameric silsesquioxanes (COSS) were investigated in the present cumulative dissertation as 
modular scaffolds for the application in biomedical engineering and associated research areas. 
Chemical modification of these unique organic-inorganic hybrids endowed them with novel features, 
aimed at functional tailoring towards executing certain biologic tasks.  
 
Within the frames of this PhD research, the chemical and structural peculiarities of COSS nanoparticles 
were used to address two parallel issues, the first one being development of a viable route to peptide 
multimers, and the second one – elaboration of a molecular platform for efficient cellular transport. 
The results of the respective studies provided the basis for four full papers and one review in peer-
reviewed scientific journals. 
 
As octakis ammonium COSS provide eight addressable sites suitable for the conjugation with peptide 
ligands, the methods allowing for their efficient functionalization were established. Taking into 
consideration poor stability of COSS scaffold in the presence of hydroxyl nucleophiles, the chemical 
route to peptide oligomers was based on efficient oxime ligation that proceeds smoothly under slightly 
acidic conditions. Thus, the amine groups crowning the flanking arms were converted to highly 
reactive aminooxy functions and those reacted with the respective peptide aldehydes. As the 
introduction of addressable carbonyls in peptides is rather good elaborated and can be achieved both 
by the methods of organic synthesis and enzymatically, the developed procedure can be applied to a 
vast number of monomers possessing peptidic structure. In the frames of present PhD research, a set of 
peptides of different size, molecular complexity and biologic functions were oligomerized on COSS 
scaffolds, among them antimicrobial and integrin-binding peptides, K-coils, and inhibitors of serine 
proteases, i.e. the therapeutically relevant ones comprising up to three disulfide bridges. It was shown 
that the bioactivity of peptide ligands was not compromised upon conjugation to COSS scaffold.    
 
Besides the establishment of the oximation method allowing for the simultaneous attachment of 
multiple peptides, different strategies were elaborated for the single-corner modification of a COSS 
framework in order to enable attachment of a solitaire peptide or other construct of interest. To this 
end, redox-labile covalent connection was realized by closure of an S-S bond at a thiol moiety installed 
by amide coupling of a single cysteine under stoichiometric control. The formation of a required 
disulfide proceeded either via oxidation with hydrogen peroxide, or upon pre-activation of one of the 
mercapto functions by 4,4’-dipyridyl disulfide. The formed bond could be easily opened as soon as the 
conjugate is exposed to the reducing environment of e.g. the cytoplasm. In addition to cleavable 
disulfide, the irreversible connection between COSS and the peptide of interest was established 
applying the version of Diels-Alder cycloaddition with inverse electron demand (DARINV). In the frame 
of the present PhD research, this pericyclic reaction was systematically investigated with respect to the 
applicability for the conjugation of structurally complex peptides and miniproteins. This highly 
efficient method was shown applicable to bioorthogonal attachment of individual peptides to the COSS 
framework. 
 
The unique molecular structure of COSS offers not only the possibility to attach multiple copies of 
desired ligands at the termini of its pendant arms. Rigid and compact, but at the same time easily 
ruptured under physiological conditions, the silsesquioxane cage provides almost perfect framework 
for the development of new-generation biodegradable cell-penetrating compounds. Indeed, 
manipulating the charge and arrangement of residues surrounding the siloxane core caused certain 
biological effects in view of membrane permeation. Thus, COSS bearing seven aminopropyl groups 
was able to deliver a 17 amino acid peptide that binds to the proliferating cell nuclear antigen in the 
nucleus of living HeLa cells. Flow-cytometry studies in mammalian revealed cellular uptake efficacy 
comparable to common cell-penetrating peptides.  
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For the functional improvement of COSS-based transporters, selected functional groups were 
covalently grafted onto the inorganic core of COSS, and linkers of different length separated both 
structural motifs. In the resulting COSS constructs, the siloxane counterpart enabled compactness of 
the whole construct and biodegradability, and the pendant groups ensured both dense positive charge 
and the hydrophobic elements required for the passage through biological membranes. The cellular 
uptake of these novel derivatives was investigated by live-cell confocal microscopic imaging and flow-
cytometry. These studies revealed improved cellular uptake for the derivatives comprising a more 
compact arrangement of the functional groups. In comparison to common cell-penetrating peptides 
(Tat, Penetratin, polyarginine) COSS bearing seven guanidinopropyl groups (GuCOSS) was 157 times 
more efficient as the Tat peptide and 35 times more efficient as the heptaarginine one. Since the 
number, nature and structure of the moieties inducing cell-penetration properties was similar for both 
transporters, this finding impressively confirms the importance of the COSS platform, which allows for 
compact and rigid assembly of guanidinium groups. In addition, unlike cell-penetrating peptides which 
need to be present above a certain concentration in order to permeate membranes, no minimal 
threshold was found for GuCOSS. Moreover, besides mammalian cells, GuCOSS-mediated cell 
penetration was observed in bacteria, yeast, and archaea.  
 
As the highly efficient GuCOSS delivery module could represent an alternative for cell-penetrating 
peptides, it was thoroughly investigated and its ability to serve as a molecular transporter was verified 
by intracellular delivery of the cytotoxic drug Doxorubicin in an in vitro assay. By using an XTT cell 
viability test, its toxicity was found comparable to cell-penetrating peptides. Furthermore, the half-life 
of the hydrolytic disassembly of the inorganic core in living HeLa cells was determined as t1/2=149 
min. As the carrier degrades under physiological conditions, intracellular as well as renal accumulation 
is prevented and the risk of an immune response is considered low. Whereas the bioavailability of free 
Doxorubicin is limited due to its poor cell permeation, its activity could be significantly improved by 
using the GuCOSS transport system. 
 
Due to the simple synthesis, highly efficient cell-penetration and a defined half-live under physiological 
conditions, the GuCOSS transport system could contribute to the toolbox of biomolecular research. As 
a platform technology for the transport of a vast number of drugs, among them small molecules, 
antibiotics, peptides, proteins, antibodies, and nucleic acids it could enable novel therapeutic 
approaches and find its way into clinical practice (potential areas for the application of COSS are 
presented in section 5.1). 
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5. Zusammenfassung 
 
Die vorliegende kumulative Dissertationsarbeit behandelt die Erforschung von Silsesquioxan 
Gerüstmolekülen im Hinblick auf unterschiedliche biomedizinische Anwendungen. Durch die 
chemische Modifikation dieser einzigartigen organisch-anorganischen Hybridmoleküle konnten 
verschiedene biologische Effekte erzielt werden.  
 
Im Rahmen der vorliegenden Forschungsarbeit wurden die chemischen und strukturellen 
Besonderheiten von Cube-octameric Silsesquioxanen (COSS) verwendet, um zwei Ziele zu erreichen: 
Erstens die Etablierung einer geeigneten Methode zur Multimerisierung von Peptiden und zweitens, 
die Entwicklung einer Plattformtechnologie für effizienten Wirkstofftransport. Die dabei erlangten 
Erkenntnisse waren die Basis für vier Manuskripte, welche nach der Begutachtung durch Experten in 
einem Peer-Review-Verfahren in Fachzeitschriften veröffentlicht wurden. 
 
Die beschriebenen Methoden ermöglichen die effiziente Biofunktionalisierung von COSS mit Peptiden, 
Miniproteinen und niedermolekularen Verbindungen. Für die Kopplung von bis zu acht strukturell 
anspruchsvollen Peptiden wurde dazu die säurekatalysierte Oxim-Ligation angewandt. Mittels dieser 
Methode konnten auch bis zu drei Cystinknoten-Miniproteine binnen weniger Stunden ans COSS 
Gerüst gekoppelt werden, wobei deren inhibitorische Aktivität gegenüber der Serinprotease Matriptase 
erhalten blieb. Da die Integrität des Hydrolyse-empfindlichen anorganischen Kerns von COSS unter 
den sauren Reaktionsbedingungen nicht gefährdet wird und die zur Kopplung benötigten 
Aldehydfunktionalitäten leicht in Biomoleküle wie Peptide, Proteine und (Poly)Saccharide eingebacht 
werden können, ermöglicht die Etablierung dieser Funktionalisierungsstrategie die Anwendung von 
COSS in der biomedizinischen Forschung.  
 
Neben der Methode zur Anbindung mehrerer Peptide wurden auch verschiedene Methoden zur 
Kopplung eines einzelnen Peptids etabliert. Die reversible Anbindung von Peptiden wurde dabei über 
eine Disulfidbrücke realisiert. Dazu wurde die Aminosäure Cystein in einer stöchiometrisch 
kontrollierten Reaktion via Amidkopplung an eine Ecke des COSS-Gerüsts gekoppelt. Das Schließen 
der Disulfidbindung gelang im Folgenden sowohl unter oxidativen Bedingungen durch den Einsatz von 
Wasserstoffperoxid als auch durch die Aktivierung mittels 4,4‘-Dipyridyldisulfid. Diese Bindung kann 
leicht unter reduzierenden Bedingungen gespalten werden, welche beispielsweise im Zytoplasma 
vorherrschen. Neben dieser reversiblen Anbindung wurde die Diels-Alder-Reaktion mit inversem 
Elektronenbedarf (DARINV) systematisch auf Ihre Eignung zur Konjugation von strukturell 
anspruchsvollen Peptiden und Miniproteinen untersucht. Damit steht diese Methode ebenfalls zur 
bioorthogonalen Anbindung einzelner Peptide an das COSS-Gerüst zur Verfügung.  
 
Die einzigartige Struktur von COSS erlaubt nicht nur die Multimerisierung von Peptiden, sondern 
eignet sich auf grund der kompakten und starren Anordnung der den anorganischen Kern umgebenden 
Gruppen geradezu ideal für die Entwicklung neuer zellpenetrierender Verbindungen. So konnte mittels 
eines mit sieben Aminopropylgruppen funktionalisierten COSS ein 17 Aminosäuren langes, das 
Proliferating Cell Nuclear Antigen bindendes Peptid funktional in lebende HeLa Zellen transportiert 
werden. Im Rahmen durchflusszytometrischer Studien mit Säugetierzellen zeigte dieser molekulare 
Transporter trotz einer geringeren Anzahl von die Zellaufnahme vermittelnden funktionellen Gruppen 
eine mit gängigen zellpenetrierenden Peptiden vergleichbare Aufnahmeeffizienz.  
 
Um verbesserte molekulare Transportsysteme zu entwickeln, wurden die funktionellen Gruppen am 
COSS Gerüst systematisch modifiziert. Dazu wurden kationische, die Zellaufnahme vermittelnde 
Gruppen, welche auch hydrophobe Strukturelemente enthalten in unterschiedlichem Abstand zum 
anorganischen Kern eingebracht. Die einzigartige Struktur von COSS ermöglichte dabei eine besonders 
kompakte Anordnung der kationischen funktionellen Gruppen. Darüber hinaus sind die auf diese 
Weise hergestellten molekularen Transporter durch den hydrolytischen Abbau des anorganischen 
Kerns unter physiologischen Bedingungen bioabbaubar. 
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Die Zellaufnahme der neu synthetisierten Derivate wurde in konfokalmikroskopischen und 
durchflusszytometrischen Studien untersucht. Dabei konnte eine verstärkte zelluläre Aufnahme im 
Falle von kompakter angeordneten funktionellen Gruppen gefunden werden. Im Vergleich zu den 
gängigen zellpenetrierenden Peptiden (Tat, Penetratin, Polyarginine) war der mit sieben 
Guanidinopropylgruppen funktionalisierte COSS (GuCOSS) rund 157 mal effizienter als Tat und ca. 35 
mal effizienter als Heptaarginin. Diese deutliche Steigerung der Aktivität bei identischer Anzahl an die 
Zellaufnahme vermittelnden funktionellen Gruppen zeigt eindrucksvoll den Einfluss der Struktur von 
COSS. Diese erlaubt die gleichermaßen kompakte und rigide Anordnung der Guanidinogruppen. Im 
Gegensatz zu zellpenetrierenden Peptiden, welche oberhalb einer minimalen Konzentration vorliegen 
müssen um zellpenetrierend zu wirken konnte für GuCOSS kein minimaler Schwellwert für die 
Zellaufnahme gezeigt werden. Im Rahmen fluoreszenzmikroskopischer Untersuchungen wurden 
zudem Hinweise auf die Penetration von Bakterien, Hefen und Archaeen gefunden.  
 
Da der hocheffiziente molekulare Transporter GuCOSS eine Alternative zu zellpenetrierenden Peptiden 
darstellt wurde er vollständig charakterisiert und als Modellsubstanz wurde das Chemotherapeutikum 
Doxorubicin im Zellkulturversuch in HeLa Zellen transportiert. Im Rahmen von XTT-basierten 
Zellviabilitätstests wurde eine mit zellpenetrierenden Peptiden vergleichbare Toxizität gefunden. 
Darüber hinaus wurde der hydrolytische Abbau des anorganischen Kerns mittels verschiedener 
Methoden untersucht und seine Halbwertszeit t1/2 in lebenden HeLa Zellen zu 149 Minuten bestimmt. 
Da GuCOSS sich unter physiologischen Bedingungen mit der Zeit zersetzt, kann sowohl die 
Akkumulation im Gewebe als auch in den Nieren verhindert werden. Zudem ist das Risiko einer 
Immunantwort als gering anzusehen. Während das freie Doxorubicin eine geringe Membrangängigkeit 
und damit eine geringe Bioverfügbarkeit aufweist, konnte seine Effizienz durch den Transport mittels 
des GuCOSS Transportsystems erheblich verbessert werden. 
 
Dank der einfacheren Synthese, der hohen Zellpenetration und einer klar definierten Halbwertszeit im 
physiologischen Umfeld könnte das GuCOSS System die biomolekulare Forschung vereinfachen. Als 
Plattformtechnologie für den Transport einer Vielzahl von Wirkstoffen wie niedermolekulare 
Verbindungen, Antibiotika, Peptide, Proteine, Antikörper und Nukleinsäuren könnte es praktische 
Anwendung im klinischen Umfeld finden und neue Therapieformen ermöglichen (potentielle 
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7. Introduction 
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The present article summarizes current applications of silsesquioxanes in biomedical research. Key 
subjects as chemical and bioothogonal modification, stability, toxicity, molecular self-organization, 
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8. Cumulative part 
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Christian Dietz, Bernhard Glotzbach, Holm Frauendorf, Harald Kolmar* and Olga Avrutina*. 
From Pico to Nano: Biofunctionalization of Cube-octameric Silsesquioxanes by Peptides and 
Miniproteins. Org. Biomol. Chem., 2012, 10, 6287-6293. Reproduced with permission of the 
Royal Society of Chemistry. 
 
8.2 Sebastian Hörner,‡ Sebastian Fabritz,‡ Henry D. Herce,* Olga Avrutina, Christian Dietz, Robert 
W. Stark, M. Cristina Cardoso and Harald Kolmar*. Cube-octameric silsesquioxane-mediated 
cargo peptide delivery into living cancer cells. Org. Biomol. Chem., 2013, 11, 2258-2265. 
Reproduced with permission of the Royal Society of Chemistry. 
 
8.3 Sebastian Hörner,‡ Christina Uth,‡ Olga Avrutina, Holm Frauendorf, Manfred Wiessler, Harald 
Kolmar*. Combination of inverse electron-demand Diels–Alder reaction with highly efficient 
oxime ligation expands the toolbox of site-selective peptide conjugations. Chem. Commun., 
2015, 51, 11130-11133. Reproduced with permission of the Royal Society of Chemistry. 
 
8.4  Sebastian Hörner,‡ Sascha Knauer,‡ Christina Uth,‡ Marina Jöst, Volker Schmidts, Holm 
Frauendorf, Christina M. Thiele, Olga Avrutina, and Harald Kolmar. Nanoscale biodegradable 
organic-inorganic hybrids for efficient cell penetration and drug delivery. Angew. Chem. Int. Ed., 
2016, 55, DOI: 10.1002/anie.201606065. Reproduced with permission of John Wiley and 
Sons.  
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The present publication introduces a conjugation strategy allowing for efficient functionalization of 
COSS nanoparticles with peptides and miniproteins. By using the acid-catalyzed oxime ligation 
between aminooxy and aldehydic groups, multimerization of different peptides and mini-proteins was 
achieved within several hours. 
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 Synthesis of compounds 2 and p5  
 NMR-Analysis of compound 2 
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8.2. Combination of inverse electron-demand Diels–Alder reaction with highly efficient 





Combination of inverse electron-demand Diels–Alder reaction with highly efficient oxime ligation 
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For the synthesis of defined peptide heterodimers and peptide conjugation to cell-penetrating COSS 
modules, the Diels-Alder reaction with inverse electron demand was combined with the oxime ligation 
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 Writing of the experimental section of the manuscript 
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Organic & Biomolecular Chemistry 
Issue 11, pages 2258-2265, December 6th 2012 
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COSS were investigated as drug delivery modules for peptide delivery into living cancer cells. A 
peptide comprising high affinity to the Proliferating Cell Nuclear Antigen (PCNA) was delivered into 
human cancer cell-line HeLa. Functionality of the peptide was proven by intracellular co-localization 
with its target. 
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 Writing of the experimental section of the manuscript 
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Nanoscale biodegradable organic-inorganic hybrids for efficient cell penetration and drug delivery 
Authors: 
Sebastian Hörner,‡ Sascha Knauer,‡ Christina Uth,‡ Marina Jöst, Volker Schmidts, Holm Frauendorf, 
Christina M. Thiele, Olga Avrutina und Harald Kolmar.  
Bibliographic Data: 
Angewandte Chemie International Edition 
Volume 55, Issue 47, November 1, 2016, Pages: 14842–14846, DOI: 10.1002/anie.201606065. 





Novel cell-penetrating COSS derivatives were synthesized and cellular uptake was compared to 
cell-penetrating peptides in three different mammalian cell lines. COSS with guanidinium groups 
(GuCOSS) efficiently translocates cellular membranes of mammalien cells, yeast, archeae, and 
bacteria. By using this biodegradable delivery module, the efficacy of cytotoxic drug Doxorubicin was 
significantly improved in an in vitro experiment. 
Contributions by Dipl.-Ing. Sebastian Hörner: 
 Conception of the manuscript 
 Design and accomplishment of chemical synthesis and interpretation of corresponding 
physicochemical analysis of compounds 2, 4, 8, 9, 12, 13, 18, 22, 23, 27, and 28 
 Design, accomplishment (50%), analysis and interpretation of flow-cytometrc experiments 
 Design, accomplishment, analysis, and interpretation of confocal microscopy and fluorescence 
microscopy studies 
 Design, accomplishment, analysis, and interpretation of degradation studies 
 Writing of the manuscript 
 Writing of the experimental section of the manuscript 
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9. Additional experimental and analytical data 
 
9.1. Experimental and analytical data appending to section 8.1 
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9.2. Experimental and analytical data appending to section 8.2 
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9.3. Experimental and analytical data appending to section 8.3 
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9.4. Experimental and analytical data appending to section 8.4 
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10. Abbreviations 
 
2-CT  2-Chlorotrityl 
3D  Three-dimensional 
A  Alanine 
AFM  Atomic force microscopy 
Ala  Alanine 
Arg  Arginine 
Asn  Asparagine 
ATR-IR  Attenuated total reflection infrared spectroscopy 
Asp  Aspartic acid 
Boc  tert-butyloxycarbonyl 
BODIPY  Boron-dipyrromethene 
C  Cysteine 
calc.  Calculated 
CD  Cyclodextrin 
CHO  Chinese hamster ovary 
CPP  Cell-penetrating peptide 
CuAAC  Copper-catalyzed azide-alkyne cycloaddition 
COSS  Cube-octameric silsesquioxane 
Cys  Cysteine 
D  Aspartic acid 
DARinv  Diels-Alder reaction with inverse electron-demand 
DCC  Dicyclohexyl carbodiimide 
DCM  Dichloromethane 
DHB  2,5-dihydroxy benzoic acid 
DIC  N,N′-Diisopropylcarbodiimide 
DIEA  N,N’-Diisopropylethylamine 
DMEM  Dulbecco's Modified Eagle's Medium 
DMF  N,N’-Dimethylformamide 
DMSO  Dimethyl sulfoxide 
DNA  Desoxyribonukleinsäure 
DOTA  1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DTT  Dithiothreitol 
E  Glutamic acid 
ECM  Extracellular medium 
EDTA  Ethylenediaminetetraacetic acid 
Eei  Ethoxyethylidene 
equiv.  Equivalent 
ESI  Electronical supplemental information 
ESI-MS  Electrospray ionization mass spectrometry 
F  Phenylalanine 
F-POSS  Flourinated polyhedral oligomeric silsesquioxane 
FBS  Fetal bovine serum 
FCS  Fetal calf serum 
Fig.  Figure 
FITC  Fluorescein isothiocyanate 
Fmoc  Fluorenylmethyloxycarbonyl chloride 
FRET  Förster resonance energy transfer 
FT-IR  Fourier transform infrared spectroscopy 
FTICR  Fourier transform ion cyclotron resonance 
G  Glycine 
Gd  Gadolinium 
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Gln  Glutamine 
Glu  Glutamic acid 
Gly  Glycine 
GuCOSS Cube-octameric silsesquioxan with guanidinium groups 
H  Histidine 
h  Hours 
HATU  1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid  
  Hexafluorophosphate 
HBTU  2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate 
HEK  Human embryonic kidney 
HEPES  2-(4-(2-Hydroxyethyl)-1-piperazinyl)-ethanesulfonic acid 
HER2  human epidermal growth factor receptor 2 
His  Histidine 
HPLC  High-performance liquid chromatography 
HR-MS  High-resolution mass spectrum 
I  Isoleucine 
ICM  Intracellular medium 
Ile  Isoleucine 
IR  Infrared 
K  Kelvin 
K  Lysine 
kHz  Kilohertz 
L  Leucine 
LC  Liquid chromatography 
LC50   Lethal concentration, 50% 
LC-MS  Liquid chromatography mass spectrometry 
Leu  Leucine 
Lys  Lysine 
µm  Micrometer 
µM  Micromolar 
M  Methionine 
M  Molar 
MALDI  Matrix-assisted laser distortion/ionization 
mRFP  Red fluorescent protein 
mg  Milligram 
meas.  Measured 
Met  Methionine 
MHz  Megahertz 
min  Minute 
mL  Milliliter 
mmol  Millimol 
MRI  Magnetic resonance imaging 
MTBE  methyl tert-butyl ether 
MTT  3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide 
N  Asparagine 
NHS  N-Hydroxysuccinimide 
nm  Nanometer 
NMR  Nuclear magnetic resonance spectroscopy 
O-POSS  Oligoelectrolyte polyhedral oligomeric silsesquioxanes 
P  Proline 
PBS  Phosphate-buffered saline 
PEG  Polyethylene glycol 
PEI  Polyethylenimine 
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Phe  Phenylalanine 
Pm  Picometer 
PCNA  Proliferating cell nuclear antigen 
POSS  Polyhedral oligomeric silsesquioxane 
Pro  Proline 
PyBOP  Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
Q  Glutamine 
R  Arginine 
RAM  Rink amide 
Rf  Retardation factor 
RFP  Red fluorescent protein 
RP-HPLC Reversed-phase high-performance liquid chromatography 
S  Second 
S  Serine 
Ser  Serine 
SNP  Silica nanoparticles 
SPPS  Solid-phase peptide synthesis 
SPAAC  Strain-promoted azide-alkyne cycloaddition 
T  Threonine 
TAMRA  Tetramethylrhodamine 
tR  Retention time 
TFA  Trifluoro acetic acid 
TEC  Thiol-ene coupling 
TES  Triethylsilane 
THF  Tetrahydrofuran 
Thr  Threonine 
TIC  Total ion current 
TLC  Thin-layer chromatography 
TOF  Time of flight 
Trp  Tryptophane 
Tyr  Tyrosine 
U  Units 
V  Valine 
Val  Valine 
W  Watt 
W  Tryptophane 
XTT  (2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2H- 
  tetrazoliumhydroxid)  
Y  Tyrosine  
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